Johnson & Johnson (NYSE:JNJ) Receives $233.73 Consensus Target Price from Brokerages

Johnson & Johnson (NYSE:JNJ) has received a consensus rating of “Moderate Buy” from the twenty-seven ratings firms that are currently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $232.6957.

JNJ has been the topic of a number of research analyst reports. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Freedom Capital downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Finally, Wolfe Research increased their target price on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th.

Insider Transactions at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently added to or reduced their stakes in the stock. Catalyst Investment Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at $496,000. Dorsey Wright & Associates purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $3,827,000. Cambient Family Office LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at about $5,848,000. White Knight Strategic Wealth Advisors LLC raised its holdings in Johnson & Johnson by 0.6% in the fourth quarter. White Knight Strategic Wealth Advisors LLC now owns 26,068 shares of the company’s stock worth $5,395,000 after buying an additional 157 shares during the last quarter. Finally, Kinloch Capital LLC lifted its stake in shares of Johnson & Johnson by 2.2% in the fourth quarter. Kinloch Capital LLC now owns 23,030 shares of the company’s stock worth $4,766,000 after buying an additional 504 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 1.9%

NYSE JNJ opened at $242.27 on Monday. The stock has a market cap of $583.86 billion, a P/E ratio of 21.93, a price-to-earnings-growth ratio of 2.35 and a beta of 0.35. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $246.96. The stock has a 50 day simple moving average of $221.06 and a two-hundred day simple moving average of $199.44. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion for the quarter. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.